ViaCyte's implant holds promise for Type 1 diabetes

06/29/2010 | MIT Technology Review

A study in mice showed that ViaCyte's implant, which contains insulin-producing cells derived from embryonic stem cells, proved to be effective in controlling blood sugar levels for four months. The San Diego-based startup is conducting safety testing that will be used in seeking FDA approval for the human trials of the technology, which is being developed as a treatment for Type 1 diabetes.

View Full Article in:

MIT Technology Review

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC